Peptide Blend Research

GLOW Peptide Pen Benefits and Side Effects: Research Data

No study has tested the GHK-Cu, BPC-157 and TB-500 blend in the GLOW peptide pen. Here is what each component shows, the one combination study, and what FDA found on safety in 2026.

·
Fact-checked · Reviewed by Remy Research Editorial Board
Update History ▾
October 27, 2026: Initial publication, built from FDA’s 2026 BPC-157 and TB-500 briefing documents, FDA’s compounding lists, a ClinicalTrials.gov search, the WADA Prohibited List and the fact-checked GHK-Cu, BPC-157 and TB-500 source sets.
Research-use-only framing applied throughout in line with Remy editorial standards.
TL;DR — Research Summary

There are no studies of the GLOW blend itself, so GLOW peptide pen benefits and side effects can only be pieced together from its three peptides: GHK-Cu, BPC-157 and TB-500. A ClinicalTrials.gov search found no registered study combining them.[1] GHK-Cu has small human trials of topical use on skin; BPC-157 has a handful of small human reports; TB-500 has no human data at all.[2][3][4]

The only combination evidence is one rat study of two of the three peptides, in which the pair did no better than either alone.[5] FDA describes the safety of injected BPC-157 and TB-500 as insufficiently characterised or unknown, and lists injectable GHK-Cu among substances with a possible immune-reaction risk.[3][4][6] No component is FDA-approved, and Remy Research supplies GLOW for in-vitro laboratory research only.

Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

What Is the GLOW Peptide Pen?

The GLOW blend includes GHK-Cu, BPC-157 and TB-500, three peptides in one product. A GLOW peptide pen is the blend supplied in a pre-filled, multi-use pen format, with the peptides already in solution; the same compounds are also sold as lyophilised (freeze-dried) powder in separate vials. The format does not change which compounds are present. Each product page lists the amount of each component. For format details, see GLOW pen vs individual peptide vials and peptide pen vs vial. KLOW adds a fourth, the KPV peptide; see GLOW vs KLOW vs Wolverine for how the blends differ.

The three were chosen because each is linked to a different part of tissue repair and tissue regeneration, but no study has tested whether combining peptides in this way gives any added benefit.[1] Every claimed glow peptide benefit, and every potential benefit attributed to the pen, is therefore borrowed from studies of a single component.

GLOW Peptide Pen Benefits: What Each Component Shows

Because the blend has not been studied, the table lists the evidence for each component separately, labelled by evidence type.

GLOW Components — Reported Effects and Evidence
Component and claim What was reported Evidence type
GHK-Cu: collagen More collagen synthesis by fibroblasts Cell culture
GHK-Cu: wrinkles Lower wrinkle volume and depth vs controls Small human trials, topical
BPC-157: repair Wound and tissue repair in rodents Animal
TB-500: wound repair LKKTETQ fragment aided repair in aged mice Animal (fragment)
BPC-157 + TB-500 No extra benefit over either alone Animal (rat tendon)
Whole GLOW blend No study exists None

GHK-Cu: Skin Health, Collagen Production and Anti-Aging Claims

GHK-Cu stimulated collagen synthesis in fibroblast cultures, and a 2018 review reports that it increases collagen and elastin production.[8][7] The same review summarises 12-week studies of topical creams in women that reported greater skin density, better skin firmness, reduced skin laxity, reduced fine lines and improved skin hydration, and lists more hair growth and larger hair follicles among GHK-Cu’s actions in experimental models.[7] In preclinical work it promotes angiogenesis and has anti-inflammatory effects through lower TGF-β and IL-6.[2] A 2026 systematic review found 18 preclinical studies and 2 randomised trials; the trials reported higher satisfaction after laser resurfacing and reduced wrinkle volume and depth, but the review noted few well-designed trials.[2] All human studies of this copper peptide tested topical products, and no human data exist for systemic use.[9] Claims that the GLOW blend can support collagen production, support skin rejuvenation, aid skin repair and skin regeneration, or improve skin elasticity rest on this topical human evidence for collagen and elastin production and for copper peptides, not on the glow blend. See GHK-Cu side effects and benefits.

BPC-157: Tissue Healing and Blood Vessel Formation

FDA’s 2026 review lists the proposed mechanisms of BPC-157: up-regulation of growth factors, suppression of inflammatory pathways, blood vessel formation and nitric oxide signalling. It identified five human studies, two reported only as conference abstracts and three small uncontrolled reports, and concluded that the data do not support its use for ulcerative colitis.[3] One of the small human reports was a chart review of patients with knee joint pain, without a control group.[3] In animal models, mostly rats, BPC-157 and similar peptides showed promising but variable effects on tendon, muscle, bone and ligament healing.[10] See BPC-157 benefits and side effects.

TB-500: Cell Migration and Wound Healing

Most wound-healing and cell migration findings attributed to TB-500 come from full-length thymosin beta-4, which binds actin, promotes cell migration and new blood vessels, and reduces inflammation and scar-forming myofibroblasts in wounds.[11] The unacetylated fragment LKKTETQ aided wound repair in aged mice, but in a 2024 fibroblast test TB-500 itself showed no significant wound-healing effect.[12][13] In rat incisional wounds the full protein organised mature connective tissue and left minimal scarring.[14] FDA found no human data on TB-500.[4] See TB-500 benefits and side effects.

Combining Peptides: BPC-157 and TB-500 Together

The only published test of two GLOW blend components together is a 2026 rat study of tissue repair after Achilles tendon injury. BPC-157 alone and TB-500 alone each improved tendon architecture, and TB-500 gave a stronger repair at four weeks; the combination conferred no additional benefit compared with either peptide alone.[5] No study has added GHK-Cu to the mix, and none has tested the blend in people.[1] A 2026 scoping review of six peptides, including all three GLOW components, judged their claimed musculoskeletal benefits unsubstantiated by current human trials.[10]

GLOW Peptide Pen Side Effects and Allergic Reactions

No adverse-event data exist for the glow blend as a product, so its potential side effects and potential risks come from findings on its components and similar mixed products:

Is the GLOW Blend FDA Approved?

Where the GLOW components stand as of October 27, 2026.
  • FDA approval. No. Neither the GLOW blend nor any of its components is an approved drug; FDA reports no approved BPC-157 product in any country.[3]
  • Compounding. BPC-157, TB-500 and injectable GHK-Cu appear on FDA’s Category 2 page as nominated but withdrawn.[6] In July 2026 FDA’s advisory committee voted 8–6 to recommend both repair peptides for the compounding list, against FDA reviewers’ advice; the votes are advisory.[17] Non-injectable GHK-Cu is in Category 1, and GHK-Cu goes to the committee before the end of February 2027.[18][19]
  • Sport. WADA prohibits BPC-157 (S0) and TB-500 (S2) at all times, so a glow blend contains two banned substances.[20]
  • UAE. The GLOW blend and its components are not registered medicines. Remy Research sells the GLOW blend for in-vitro laboratory research only, not for human use or veterinary use.

GLOW vs Individual Peptides and Other Blends

The GLOW blend puts three separately studied peptides in one product. For research design this means any effect observed with the glow peptide cannot be assigned to one component without separate arms. For the format comparison, see GLOW pen vs individual peptide vials; for the proposed rationale behind the combination, see the GLOW blend mechanism review; and for BPC-157 against TB-500 alone, see BPC-157 vs TB-500.

What the Research Does Not Yet Show

GLOW for Laboratory Research

Remy Research supplies the GLOW blend for in-vitro lab research as the GLOW 70mg pen and the Genovare GLOW 200mg AQ pen. Each glow blend product page carries its composition and batch testing details. For the market background, see GLOW peptide blend in Dubai.

Our Research Standards

This article prioritizes primary literature, trial registries and regulator records, and keeps the evidence for each component separate because the blend itself has not been studied. No therapeutic, dosing, preparation or administration guidance is given. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

GLOW Peptide Pen Benefits and Side Effects FAQ

What are the benefits of the GLOW peptide?

No study has tested the GLOW blend as a whole. Its components have reported effects in their own studies: GHK-Cu on collagen and wrinkles in small topical trials, and BPC-157 and TB-500 on tissue repair, mostly in animals.[2][3][12]

What are the side effects of the GLOW peptide?

Side effects of the glow blend have not been studied. FDA reports skin and gum darkening after a product containing both repair peptides, and warns of possible immune reactions to injected BPC-157, TB-500 and GHK-Cu.[3][6]

What is in the GLOW peptide blend?

Three peptides: GHK-Cu, a copper-binding tripeptide; BPC-157, a 15-amino-acid synthetic peptide; and TB-500, a seven-amino-acid fragment of thymosin beta-4.[7][3][4]

What is a GLOW peptide pen?

A pre-filled, multi-use pen that holds the GLOW blend already in solution, as opposed to lyophilised powder in separate vials. See the GLOW pen vs individual peptide vials comparison for format details.

Is the GLOW peptide FDA approved?

No. None of its components is an approved drug, and BPC-157, TB-500 and injectable GHK-Cu are listed on FDA’s Category 2 page as nominated but withdrawn.[3][6]

Is the GLOW peptide safe?

The glow blend’s safety is unknown. FDA judged the safety information for BPC-157 insufficient and the human risks of TB-500 unknown.[3][4]

Does combining BPC-157 and TB-500 work better?

In the one rat tendon study that tested it, the combination gave no additional benefit over either peptide alone.[5]

What is the difference between GLOW and KLOW?

KLOW contains the same three peptides as GLOW plus KPV, a short anti-inflammatory peptide. See the GLOW vs KLOW vs Wolverine comparison.

Is GLOW banned in sport?

Two GLOW blend components are: WADA prohibits BPC-157 and TB-500 at all times.[20]

Sources

  1. ClinicalTrials.gov API search for studies mentioning both BPC-157 and GHK-Cu (query “BPC-157 AND GHK-Cu”): zero records, checked October 27, 2026. clinicaltrials.gov ↩
  2. Mokhtar J, Mohamad B, Haddad J, et al. The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthet Surg J. 2026 (online August 20, 2026):sjag169. doi: 10.1093/asj/sjag169 · PMID: 42619529 ↩
  3. U.S. Food and Drug Administration. FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. fda.gov/media/193343 ↩
  4. U.S. Food and Drug Administration. FDA Briefing Document: TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate). Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. fda.gov/media/193349 ↩
  5. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. doi: 10.52312/jdrs.2026.2951 · PMID: 42542926 The paper describes its TB-500 as synthetic thymosin beta-4 and does not state its sequence. ↩
  6. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2; BPC-157, “GHK-Cu (for injectable routes of administration)” and “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500” under “Bulk drug substances nominated but withdrawn”). Updated April 22, 2026; checked October 27, 2026. fda.gov ↩
  7. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi: 10.3390/ijms19071987 · PMID: 29986520 ↩
  8. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. doi: 10.1016/0014-5793(88)80509-x · PMID: 3169264 ↩
  9. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics. 2026;18(9):1077. doi: 10.3390/pharmaceutics18091077 · PMID: 42797253 ↩
  10. Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026 (online August 11, 2026). doi: 10.1177/03635465261464420 · PMID: 42578445 ↩
  11. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi: 10.1517/14712598.2012.634793 · PMID: 22074294 ↩
  12. Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. doi: 10.1046/j.1524-475x.2003.11105.x · PMID: 12581423 ↩
  13. Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. doi: 10.1016/j.jchromb.2024.124033 · PMID: 38382158 ↩
  14. Ehrlich HP, Hazard SW. Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. Ann N Y Acad Sci. 2010;1194:118-124. doi: 10.1111/j.1749-6632.2010.05483.x · PMID: 20536458 ↩
  15. Li H, Toh PZ, Tan JY, et al. Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Sci Rep. 2016;6:37664. doi: 10.1038/srep37664 ↩
  16. Delcourt V, Garcia P, Chabot B, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458-464. doi: 10.1002/dta.3421 · PMID: 36482504 ↩
  17. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC, July 31, 2026. ajmc.com ↩
  18. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Category 1 lists “GHK-Cu (except for injectable routes of administration)”). Updated May 14, 2026. fda.gov/media/94155 ↩
  19. U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027; LL-37, GHK-Cu, dihexa acetate, Melanotan II, PEG-MGF). Checked October 27, 2026. fda.gov ↩
  20. World Anti-Doping Agency. The Prohibited List (S0 names BPC-157; S2 names “Thymosin-β4 and its derivatives e.g. TB-500”; both prohibited at all times). Checked October 27, 2026. wada-ama.org ↩

For catalog details, see the GLOW 70mg pen and the Genovare GLOW 200mg AQ pen. For editorial standards, continue to the editorial policy.

Related Research

Catalog GLOW 70mg Pen→ Mechanism GLOW Blend Mechanism Review→ Comparison GLOW vs KLOW vs Wolverine→ Copper Peptide GHK-Cu Side Effects & Benefits→ Healing Peptide BPC-157 Benefits & Side Effects→ Healing Peptide TB-500 Benefits & Side Effects→ Format GLOW Pen vs Individual Vials→ Catalog Research Peptide Catalog→